Clinical and pharmacological determinants of serum dexamethasone concentrations during dexamethasone suppression test

Clicks: 8
ID: 327920
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #290 of 383 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 383 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: The 1-mg overnight dexamethasone suppression test (1-mg DST) is widely used to screen for hypercortisolism, but its interpretation may be affected by variability in dexamethasone exposure due to clinical and pharmacological factors. OBJECTIVE: To evaluate determinants of serum dexamethasone levels during 1-mg DST and their impact on test interpretation. METHODS: Observational study including 546 patients undergoing 1-mg DST with measurement of serum cortisol and dexamethasone levels. Clinical variables (age, BMI, eGFR) and concomitant medications were analyzed. Associations with dexamethasone levels were assessed using multivariable linear regression; suboptimal exposure (<4.5 nmol/L) was evaluated by logistic analysis. RESULTS: Median dexamethasone concentration was 11.9 nmol/L. In multivariable analysis, age (β=0.24, p<0.001) and BMI (β=0.17, p=0.010) were independently associated with higher dexamethasone levels, whereas eGFR was not. Concomitant medications (PPIs, statins, calcium channel blockers) were associated with higher dexamethasone levels in univariable analyses, but not after sensitivity analyses. Age-stratified models showed that BMI and PPI use were associated with dexamethasone in patients <65 years, whereas statins and PPIs were determinants in those ≥65 years. BMI and eGFR remained significant after excluding patients with mild autonomous cortisol secretion. Suboptimal dexamethasone exposure occurred in 3.3% of patients and was frequently associated with inadequate cortisol suppression. CONCLUSIONS: Age and BMI emerged as determinants of dexamethasone exposure during 1-mg DST, while the impact of renal function and medications appears limited after adjustment. Measuring dexamethasone may improve test interpretation; however, once adequate dexamethasone exposure is achieved, higher dexamethasone levels are not associated with additional cortisol suppression.
Reference Key
openalex_W7211954196 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Irene Tizianel, Giorgia Antonelli, Alessandro Mondin, Andrea Cignarella, Pierluigi Mazzeo, Giulia Bovo, Martina Montagnana, Mattia Barbot, Filippo Ceccato
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag370
URL
https://doi.org/10.1210/clinem/dgag370
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.